中低危急性心肌梗死合并糖尿病患者植入生物可降解支架的预后研究  

Prognostic Study of Biodegradable Stent in Patients with Middle,Low Risk Acute Myocardial Infarction Complicated with Diabetes Mellitus

作　　者：童金英 刘江 柯小云 官华芳 赖晶 TONG Jinying;LIU Jiang;KE Xiaoyun;GUAN Huafang;LAI Jing(Yingtan City People's Hospital,Jiangxi Province,Yingtan 335000,China;不详)

机构地区：[1]江西省鹰潭市人民医院,江西鹰潭335000

出　　处：《中国医学创新》2023年第30期138-142,共5页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(202140651)。

摘　　要：目的:探讨中低危急性心肌梗死合并糖尿病患者植入生物可降解支架(BRS)的效果及安全性。方法:选取2020年6月—2021年6月在鹰潭市人民医院接受治疗的128例中低危急性心肌梗死合并糖尿病患者作为研究对象,根据随机数字表法将其分为对照组(n=64)和观察组(n=64),所有患者均接受经皮冠状动脉介入术(PCI),对照组植入生物可降解聚合物涂层药物洗脱支架(BP-DES),观察组植入BRS。对比两组术后1、12个月主要心血管不良事件(MACE)、净不良临床事件(NACE),并比较两组炎症指标[超敏C反应蛋白(hs-CRP)、脂蛋白相关磷脂酶A2(Lp-PLA2)]变化情况。结果:术后1、12个月,观察组与对照组MACE发生率比较,差异均无统计学意义(P>0.05);术后1、12个月,观察组与对照组NACE发生率,差异均无统计学意义(P>0.05);术前及术后3 d、6个月,两组患者hs-CRP、Lp-PLA2比较,差异均无统计学意义(P>0.05)。结论:BRS用于心肌梗死合并糖尿病的治疗中,术后1年内的效果与安全性与DES相当。Objective:To investigate the efficacy and safety of biodegradable stent(BRS)implantation in patients with middle,low risk acute myocardial infarction complicated with diabetes mellitus.Method:A total of 128 patients with middle,low risk acute myocardial infarction complicated with diabetes mellitus who received treatment in Yingtan City People's Hospital from June 2020 to June 2021 were selected as the study objects,and were divided into control group(n=64)and observation group(n=64)according to random number table method.All patients underwent percutaneous coronary intervention(PCI),and the control group was implanted biodegradable polymers drug eluting stent(BP-DES),the observation group was implanted BRS.Major adverse cardiovascular events(MACE)and net adverse clinical events(NACE)were compared between the two groups at 1 and 12 months after surgery,and the changes of inflammatory indicators(hypersensitive C reactive protein(hs-CRP)and lipoprotein-associated phospholipase A2(Lp-PLA2)were compared between the two groups.Result:At 1 and 12 months after surgery,there were no significant differences in the incidences of MACE between the observation group and the control group(P>0.05).At 1 and 12 months after surgery,there were no significant differences in the incidences of NACE between the observation group and the control group(P>0.05).There were no significant differences in hs-CRP and Lp-PLA2 between two groups before surgery and 3 d and 6 months after surgery(P>0.05).Conclusion:The efficacy and safety of BRS in the treatment of myocardial infarction complicated with diabetes mellitus within 1 year after surgery are comparable to DES.

关 键 词：急性心肌梗死 药物洗脱支架 生物可降解支架 预后 

分 类 号：R542.22[医药卫生—心血管疾病] R587.2[医药卫生—内科学]